Heart Failure & Diabetes Research Study
Researchers at UT Health San Antonio are conducting a research study to better understand heart failure and diabetes.
Fast Facts
Diagnosed with Heart Failure and Type 2 Diabetes
18-80 Years Old
Compensation Provided
Conducted in San Antonio, TX
Study Background
Researchers at UT Health San Antonio are conducting a research study on individuals ages 18-80 to understand Ketones, Muscle Metabolism, and SGLT2 Inhibitors in the presence of heart failure and diabetes.
We’re studying how SGLT2 inhibitors work differently in people with diabetes and heart failure with reduced ejection fraction.
We’re looking at changes in plasma ketones (β-OH-B and acetoacetate) at the start and end of the study, along with heart function measures, improvements in blood sugar levels, and the decrease in plasma ketone levels during the last 8 days of the study.
Eventually, the findings of this study might be useful for treating heart failure and diabetes.
Study Background
Researchers at the University of Texas Health Science Center at San Antonio are conducting a research study on individuals ages 18-80 to understand Ketones, Muscle Metabolism, and SGLT2 Inhibitors in the presence of heart failure and diabetes.
We’re studying how SGLT2 inhibitors work differently in people with diabetes and heart failure with reduced ejection fraction. We’re looking at changes in plasma ketones (β-OH-B and acetoacetate) at the start and end of the study, along with heart function measures, improvements in blood sugar levels, and the decrease in plasma ketone levels during the last 8 days of the study
Eventually, the findings of this study might be useful for treating heart failure and diabetes.
Additional Information
In this research study, we’re studying how SGLT2 inhibitors work differently in people with diabetes and heart failure with reduced ejection fraction.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- 18-80 years old
- Diagnosed with heart failure
- Diagnosed with type 2 diabetes
Participants will be asked to attend up to 16 visits. Participants are assigned to one of 2 study groups that will receive a 12-week treatment with either Empagliflozin or a placebo. At the end of the 12-week treatment, study participants will receive an 8-day treatment with Acipimox with either Empagliflozin or a placebo.
The entire study lasts 13 weeks.
As a participant, you can receive up to $2000.
There is no cost for you to participate in our research study.